



31 **ABSTRACT**

32 **IMPORTANCE**

33 Since December, 2020, the ID NOW was implemented for use in 4 different populations across  
34 Alberta: in mobile units as part of community outbreak response, COVID-19 community  
35 collection sites, emergency shelters and addiction treatment facilities (ES), and hospitals.

36 **OBJECTIVE**

37 Diagnostic evaluation of the ID NOW in various real world settings among symptomatic and  
38 asymptomatic individuals

39 **DESIGN**

40 Depending on the implemented site, the ID NOW was tested on patients with symptoms  
41 suggestive of COVID-19, asymptomatic close contacts or asymptomatic individuals as part of  
42 outbreak point prevalence screening. From Jan – April, a select number of sites also switched  
43 from using oropharyngeal swabs to combined oropharyngeal + nasal (O+N) swabs. For every  
44 individual tested, two swabs were collected: one for ID NOW testing and the other for either  
45 reverse-transcriptase polymerase chain reaction (RT-PCR) confirmation of negative ID NOW  
46 results or for variant testing of positive ID NOW results.

47 **RESULTS**

48 A total of 129,112 paired samples were analyzed (16,061 RT-PCR positive). 81,697 samples  
49 were from 42 COVID-19 community collection sites, 16,924 from 69 rural hospitals, 1,927 from  
50 9 ES, 23,802 samples from 6 mobile units that responded to 356 community outbreaks, and  
51 4,762 from 3 community collection sites and 1 ES using O+N swabs for ID NOW testing. ID  
52 NOW sensitivity was highest among symptomatic individuals presenting to community  
53 collection sites [92.5%, 95% confidence interval (CI) 92.0-93.0%, n=10,633 RT-PCR positive]  
54 and lowest for asymptomatic individuals associated with community outbreaks (73.9%, 95% CI  
55 69.8-77.7%, n=494 RT-PCR positive). Specificity was greater than 99% in all populations tested,  
56 but positive predictive value (PPV) was lower among asymptomatic populations (82.4–91.3%)  
57 compared to symptomatic populations (96.0-96.9%). There was no statistically significant  
58 differences in sensitivity with respect to age, gender, NP vs OP swab for RT-PCR confirmation,  
59 variants of concern, or with combined oropharyngeal and nasal swabs using COVID-19 ID  
60 NOW testing.

61 **CONCLUSIONS**

62 Sensitivity of ID NOW SARS-CoV-2 testing is highest when used on symptomatic community  
63 populations not seeking medical care. Sensitivity and PPV drops by approximately 10% when  
64 tested on asymptomatic populations. Using combined oropharyngeal and nasal swabs did not  
65 improve ID NOW performance.

66

67 **Keywords:** ID NOW, COVID-19, SARS-CoV-2, POCT, rapid diagnostics, symptomatic,

68 asymptomatic

69

70

71 **INTRODUCTION**

72 The ID NOW (Abbott, Illinois, United States) is approved by the United States Food and Drug  
73 Administration (FDA) Emergency Use Authorization for the point of care, rapid detection of  
74 severe acute respiratory syndrome-coronavirus-2 (SARS-CoV-2) in individuals who are within  
75 the first 7 days of symptom onset.<sup>1</sup> The ID NOW assay uses isothermal nucleic acid  
76 amplification of a region of the viral RNA-dependent RNA polymerase (RdRp) to detect the  
77 presence of SARS-CoV-2, with results available in under 15 minutes. Clinical specimens  
78 approved by U.S. FDA for testing include nasal, oropharyngeal, and nasopharyngeal swabs (NP),  
79 which must be tested on the Abbott ID NOW either immediately or within one hour of  
80 collection. Specimens placed in viral/universal transport media (UTM) are not valid for testing  
81 by the Abbott ID NOW.<sup>1</sup>

82  
83 There are many studies that have evaluated the Abbott ID NOW. Its analytical sensitivity  
84 approximates 250-500 copies/mL and is significantly higher compared to other lab based RT-  
85 PCR platforms, which are typically under 200 copies/mL.<sup>2,3</sup> Pooled clinical sensitivity of the ID  
86 NOW from 13 studies, compared to RT-PCR, was 73.0% (95% CI 66.8% - 78.4%), and  
87 specificity was 99.7% (95% CI 98.7% - 99.4%).<sup>4</sup> However, these studies were limited in sample  
88 size and heterogeneous in design, such as in differences in specimen type and RT-PCR reference  
89 method used. There is also a paucity of data on ID NOW performance in asymptomatic  
90 individuals. This is important because ID NOW performance may be negatively affected among  
91 asymptomatic individuals with COVID-19, given the higher cycle threshold (Ct) values observed  
92 in this population.<sup>5</sup>

93

94 This study sought to accomplish two goals. The first was to prospectively evaluate the clinical  
95 performance of the ID NOW, compared to RT-PCR, after its implementation for SARS-CoV-2  
96 testing in various settings across the province of Alberta, Canada (4.4 million people). Based on  
97 its rollout, we evaluated the clinical sensitivity and specificity of the ID NOW in these four  
98 settings:

- 99 1) Symptomatic individuals or asymptomatic close contacts presenting to community COVID-19  
100 assessment/swab centres.
- 101 2) Symptomatic inpatients or Emergency Department patients.
- 102 3) Symptomatic individuals in emergency shelters and addiction treatment facilities.
- 103 4) Symptomatic or asymptomatic individuals associated with community outbreaks (majority in  
104 continuing care centres).

105  
106 The second aim of this study was to compare the differences in sensitivity/specificity between  
107 the use of oropharyngeal swabs vs combined oropharyngeal and nasal (O+N) swabs for ID NOW  
108 testing in two different COVID-19 testing settings: assessment centres and emergency shelters  
109 and addiction treatment facilities. Although oropharyngeal swabs have slightly lower sensitivity  
110 compared to nasopharyngeal swab for SARS-CoV-2 detection by RT-PCR, several studies have  
111 demonstrated improved sensitivity with O+N swabs.<sup>6-8</sup>

112

## 113 **METHODS**

114 Since December 4, 2020, the ID NOW was gradually implemented across Alberta in the  
115 following sites:

116 1) 42 COVID-19 Alberta Health Services (AHS) Public Health assessment/swabbing centres,  
117 located in all regions of Alberta: testing of symptomatic individuals and asymptomatic close  
118 contacts. These are the primary locations for community patients not needing medical attention  
119 to get tested for COVID-19 in Alberta. Testing and swabbing was performed by assessment  
120 centre staff (e.g. nurses) within Alberta Precision Laboratories (APL) approved Point of Care  
121 Testing (POCT) programs.

122 2) 69 rural hospitals located across Alberta: testing of symptomatic inpatients or ED patients.  
123 Swabbing was performed by physicians, nurses, or respiratory therapists. Testing was performed  
124 in a College of Physician and Surgeons of Alberta (CPSA) accredited hospital laboratory (APL).

125 3) 9 emergency/homeless shelters and addiction treatment facilities, located in urban centres in  
126 Alberta: testing of symptomatic residents. Testing and swabbing performed on site by registered  
127 nurses.

128 4) 6 mobile units that accessed all regions of Alberta: testing of symptomatic or asymptomatic  
129 residents or staff, all from organizations on outbreak (majority were continuing care sites).  
130 Swabbing and testing performed by mobile nursing team staff on-site in retrofitted vans.  
131

132 Individuals were given the option to have POCT by ID NOW and routine testing, or routine  
133 testing alone. All individuals tested with the ID NOW had two parallel swabs collected. The first  
134 swab collected was either a NP swab or oropharyngeal (OP) swab, which was placed in UTM  
135 (Yocon Biology, Beijing, China or GDL Korea Co. Ltd, Seoul, Korea) for RT-PCR, and  
136 transported to an accredited laboratory at room temperature and stored at 4°C until processing.  
137 The second swab was an OP swab for ID NOW testing (using the OP swab provided in the ID  
138 NOW kits). The OP swab for ID NOW testing was always collected second to ensure all

139 individuals had a sample available for RT-PCR (i.e. in case the individual refused the second NP  
140 or OP swab). If the ID NOW test was negative, the second swab was sent for confirmatory RT-  
141 PCR testing. If the ID NOW test was positive, the second swab was either sent for storage (if  
142 collected before February 1, 2021) or for variant of concern screening (VoC) testing. Samples  
143 sent for storage (-70°C) were tested at a later date for SARS-CoV-2 using RT-PCR. All RT-PCR  
144 tests sent for variant testing were done within approximately 72 hours from time of collection.

145  
146 All RT-PCR testing was performed on the APL Public Health Laboratory E gene PCR or on a  
147 Health Canada and FDA approved commercial assay.<sup>9</sup> Commercial assays were dependent on  
148 the testing lab and included the Allplex (Seegene, Seoul, South Korea), BDMax (Becton  
149 Dickinson, NJ, United States), Panther (Hologic, MA, United States), GeneXpert SARS-CoV-2  
150 or SARS-CoV-2/Influenza/RSV (Cepheid, CA, United States), Cobas 6800 System (Roche  
151 Molecular Systems, CA, United States) and Simplexa (DiaSorin, Saluggia, Italy). All samples  
152 sent for VoC screening were tested with the ProvLab E gene assay to determine if sufficient viral  
153 load was present for VoC testing. E gene RT-PCR results from our lab-developed test were  
154 considered positive for SARS-CoV-2 when E gene cycle threshold (Ct) value was <35.  
155 If the Ct was  $\geq 35$ , amplification from the same eluate was repeated in duplicate and was  
156 considered positive if at least 2/3 results had a Ct <41.

157  
158 All personnel performing the ID NOW swabbing/testing were trained healthcare workers  
159 (HCW), who were previously trained in NP and oropharyngeal swab collection. At time of  
160 collection, they asked and recorded whether the patient had symptoms or was asymptomatic. All  
161 sites and HCW were trained on the ID NOW collection, transport, and testing processes, at least

162 according to the manufacturer's instructions, prior to ID NOW implementation. AHS staff were  
163 trained according to the APL POCT program, which meets CPSA accreditation standards. Each  
164 ID NOW device underwent a verification process, which included testing 3 positive ID NOW  
165 control swabs and 5 negative ID NOW control swabs on the ID NOW instrument before use.  
166 One positive control and one negative control swab were tested on the ID NOW instrument after  
167 each new box of ID NOW kits was opened, after each new HCW was trained on the instrument,  
168 and, after each instrument was transported to a different site.

169  
170 All ID NOW samples with parallel RT-PCR results documented were included in our study.  
171 Results without proper documentation of testing location, or without either confirmatory RT-  
172 PCR or variant testing were excluded.

173  
174 Between Jan 26 and April 12, 2021, 3 assessment centres and one shelter and addiction treatment  
175 facility switched from using oropharyngeal swabs to O+N swabs for ID NOW testing. The swab  
176 used remained the same (swab provided in Abbott ID NOW kits) and instructions for swabbing  
177 was provided to individual sites (see supplementary material for instruction details). All other  
178 protocols, as outlined above, remained in place.

179  
180 Data was pulled from our provincial laboratory's centralized electronic database containing  
181 SARS-CoV-2 results for all publicly funded testing in the province except for border testing.  
182 Sensitivity and specificity of the ID NOW was calculated with Clopper-Pearson 95% confidence  
183 intervals. Statistical analysis was performed using Pearson Chi-squared for categorical variables  
184 and t-test for continuous variables using STATA (version 14.1).

185 The University of Alberta Research Ethics board approved this study (Pro00111835).

186

## 187 **RESULTS**

188 A total of 133,919 results were identified between December 4, 2020 and November 24, 2021.

189 4807 samples were excluded: 190 did not have testing location recorded, 375 did not have an ID

190 NOW result recorded, 3 had invalid ID NOW results, 2,417 ID NOW results did not have

191 parallel RT-PCR results recorded, and 1,822 positive ID NOW results did not have subsequent

192 variant testing performed. The remaining 129,112 paired samples were analyzed.

193

### 194 ID NOW testing using oropharyngeal swabs

195 124,350 samples (15,649 RT-PCR positive) were analyzed. 81,697 samples were from 42

196 assessment centres, 16,924 samples were collected from 69 rural hospitals, 1,927 samples were

197 from 9 shelters and addiction treatment facilities, and 23,802 samples were from 6 mobile units

198 that responded to 356 outbreaks. Baseline characteristics of these samples is provided in Table 1.

199 Results, compared to RT-PCR, are provided in Table 2 and Figure 1. ID NOW sensitivity was

200 highest among symptomatic individuals presenting to assessment centres [92.5%, 95%

201 confidence interval (CI) 92.0-93.0%, n=10,633 RT-PCR positive], and lowest for asymptomatic

202 individuals associated with community outbreaks (73.9%, 95% CI 69.8-77.7%, n=494 RT-PCR

203 positive). There was an approximate 10% decrease in sensitivity when testing asymptomatic vs

204 symptomatic populations. Specificity was greater than 99% in all populations tested.

205

206 Positive predictive value (PPV) was highest for symptomatic individuals presenting to

207 assessment centres (PPV 96.9%, 95% CI 96.5-97.2%), followed by symptomatic patients in



208 hospital or emergency rooms (96.4%, 95% CI 95.7-97.1%), symptomatic patients tested via  
209 mobile units (96.0%, 94.1-97.3%), asymptomatic individuals presenting to assessment centres  
210 (91.3%, 95% CI 89.2-93.1%), symptomatic individuals at emergency shelters and addiction  
211 treatment facilities (88.6%, 95% CI 79.3-94.0%) and asymptomatic patients tested via mobile  
212 units (82.4%, 95% CI 78.8-85.5%). Negative predictive value (NPV) was highest for  
213 asymptomatic patients tested via mobile units (99.3%, 95% CI 98.8-99.1%), symptomatic  
214 individuals at emergency centres and addiction treatment facilities (99.0%, 95% CI 98.5-99.3%),  
215 symptomatic individuals presenting to assessment centres (98.7%, 95% CI 98.6-98.8%),  
216 asymptomatic individuals presenting to assessment centres (98.6%, 95% CI 98.3-98.8%),  
217 symptomatic patients tested via mobile units (98.0%, 95% CI 97.6-98.4%), and symptomatic  
218 patients in hospital or emergency rooms (97.8%, 95% CI 97.6-98.0%).

219  
220 Ct values for ID NOW true positive and true negative results is provided in Table 3. Mean E  
221 gene Ct values were significantly higher among ID NOW false negatives compared to true  
222 positives and among asymptomatic compared to symptomatic populations, with the exception of  
223 mean E gene Ct value of false negatives between symptomatic vs asymptomatic in mobile testing  
224 and in assessment centres using O+N swabs ( $p>0.05$ ).

225  
226 There was no significant difference in sensitivity and specificity of ID NOW when comparing  
227 symptomatic and asymptomatic patients under 5 years of age, under 10 years of age, under 18  
228 years of age, and over 18 years of age (Supplementary Table 1-4). There was no significant  
229 difference in sensitivity and specificity of ID NOW when comparing symptomatic and  
230 asymptomatic patients based on gender (Supplementary Table 5-6).

231  
232 There was no significant difference in sensitivity when a NP or OP swab for confirmatory RT-  
233 PCR (or variant) testing was done among symptomatic or asymptomatic patients (Supplementary  
234 Table 7-8). However, there was slight differences in specificity, with OP swabs having higher  
235 specificity compared to NP swabs. There was no significant difference in sensitivity between  
236 symptomatic or asymptomatic patients with alpha compared to the delta variant (Supplementary  
237 Table 9-10).

238

#### 239 ID NOW testing using combined oropharyngeal and nasal swabs

240 4,762 paired samples were analyzed (412 RT-PCR positive). 4,571 samples were from 3  
241 assessment centres and 191 samples were collected from 1 urban emergency shelter. Baseline  
242 characteristics of these samples is provided in Table 1. ID NOW results, compared to RT-PCR,  
243 are provided in Table 2. There was no statistically significant differences in sensitivity or  
244 specificity noted between results from ID NOW using oropharyngeal swabs and those using  
245 O+N swabs (Figure 2).

246

247

## 248 **DISCUSSION**

249 Use of point of care SARS-CoV-2 tests, such as the ID NOW, for the detection of SARS-CoV-2  
250 among individuals remains a worthwhile endeavour. Even if confirmatory testing of negatives is  
251 performed, identifying positives at the point of care has several advantages. It can speed  
252 important public health measures, such as contact tracing and isolation. Moreover, it has  
253 significant benefits for the laboratory in terms of decreasing contamination error and improving  
254 laboratory processes. For instance, decreasing the number of positive samples entering the

255 laboratory can decrease the risk of false positive results by reducing the probability of SARS-  
256 CoV-2 contamination during RT-PCR testing. In addition, the decrease in positive samples can  
257 improve efficiencies in other laboratory processes, such as pooling.

258

259 In our large, multicentre, population-based study, we observed differing ID NOW sensitivities,  
260 compared to RT-PCR, based on the population being tested. Sensitivity was highest (92.5%)  
261 when tested among symptomatic individuals presenting to community COVID-19 assessment  
262 centres and lowest for asymptomatic individuals associated with community outbreaks (73.9%,  
263 95% CI 69.8-77.7%, n=494 RT-PCR positive). These results highlight that the ID NOW  
264 performance is not standard across populations tested, likely as a result of its poorer performance  
265 with lower viral loads, as can be observed among asymptomatic individuals or individuals who  
266 are further out from their symptom onset.<sup>5</sup> This outcome can better help direct where ID NOW  
267 devices are most suitable, and provide information to consider when goals of testing are  
268 reviewed. As expected, we observed lower average E gene Ct values among symptomatic  
269 individuals compared to asymptomatic individuals and among ID NOW false negative compared  
270 to true positive samples. Higher Ct values observed in results from emergency shelters and  
271 addiction treatment facilities is likely a manifestation of the unique population being tested.  
272 While testing was limited to individuals with symptom onset within the first 7 days, it can be  
273 challenging to differentiate those with symptoms in these settings, particularly those who spend  
274 frequent time outside in the cold (i.e. rhinorrhea), and have fluctuating symptoms related to other  
275 factors such as drug use.

276

277 ID NOW sensitivity was slightly lower in the symptomatic populations tested using a mobile  
278 service or in-hospital based settings. There may be various factors to account for this. Firstly, ID  
279 NOW testing is performed immediately after sample collection at assessment centres, whereas  
280 hospitals and mobile service often require transportation to the on-site lab or mobile unit prior to  
281 ID NOW testing. While ID NOW testing was mandated to be done within 1 hour from  
282 collection, short periods of time from transportation may potentially affect performance.<sup>10</sup>  
283 Secondly, a higher proportion of individuals with lower viral loads may be tested in hospitals and  
284 via mobile. For mobile testing (mostly outbreaks), individuals with symptoms were possibly  
285 early in their symptom onset at time of testing, whereas those presenting to hospitals were  
286 possibly late in their symptom onset; both of which can be associated with higher Ct values and,  
287 therefore, lower viral loads.<sup>5</sup> Symptomatic individuals presenting to assessment centres, in  
288 comparison, are often within the first few days of symptom onset, but because it generally takes  
289 approximately 24 hours to arrange a booking, are not at the very beginning of their symptom  
290 onset.

291  
292 There are clear differences in ID NOW sensitivity with respect to symptoms, with asymptomatic  
293 populations having an approximately 10% decrease in sensitivity. There were significantly  
294 higher mean E gene Ct values observed when testing asymptomatic versus symptomatic  
295 individuals in assessment centres. This has important implications when using the ID NOW for  
296 screening of asymptomatic populations, where the implications of a rapid test for such a  
297 population needs to be carefully considered and weighed over the risks of a substantial decrease  
298 in sensitivity compared to other testing methods (RT-PCR). However, the sensitivity of the ID

299 NOW compared to other point of care options, including rapid antigen tests, is far superior, with  
300 the sensitivity of rapid antigen tests ranging from 30-50% in asymptomatic populations.<sup>4</sup>

301  
302 ID NOW sensitivity in our study is underestimated due to the large number (1,822, 11.3% of  
303 positives) of ID NOW positives that were excluded from our analysis, 93% of which came from  
304 symptomatic individuals from assessment centres. These were excluded due to the lack of  
305 parallel RT-PCR testing. If these excluded samples were included as true positives, sensitivity of  
306 symptomatic individuals presenting to assessment centres would increase to 93.5% (95% CI  
307 93.0-93.9%).

308  
309 ID NOW specificity was consistently high across the populations tested (>99%), and is  
310 consistent with prior studies within the literature.<sup>4</sup> When comparing ID NOW to RT-PCR from  
311 individuals with confirmed COVID-19, we previously demonstrated a significant number of ID  
312 NOW positive, RT-PCR negative discrepant results.<sup>10</sup> This suggests that other factors may  
313 account for discrepant results, such as sampling error. It is noted that multiple individuals within  
314 our dataset had an ID NOW positive result followed by subsequent negative RT-PCR, but then  
315 on repeat RT-PCR the next day were positive. These patients were considered ID NOW false  
316 positives in our study, although in reality would be considered true positives based on this  
317 information. As such, ID NOW specificity is likely higher than what we have reported. Although  
318 the exclusion of many ID NOW positive results in our study may contribute to overestimation of  
319 ID NOW specificity, this would be primarily limited to symptomatic individuals at assessment  
320 centres, and would have little to no impact on the specificity observed among other populations  
321 studied.

322

323 Using an oropharyngeal swab or O+N swab for ID NOW testing yielded similar results among  
324 both symptomatic and asymptomatic populations. Given the higher inconvenience with O+N  
325 swabs, and the lack of advantages demonstrated over typical specimens, we recommend against  
326 using O+N swabs for ID NOW COVID-19 testing.

327

328 Strengths of this study include the large sample size and including both symptomatic and  
329 asymptomatic populations. We also studied testing in various real world locations, including  
330 community COVID-19 assessment centres, hospitals (inpatient and ED), emergency shelters and  
331 addiction treatment facilities, and continuing care and industry outbreaks. Due to the introduction  
332 of mandatory testing of many positive ID NOW or RT-PCR samples for variants of concern,  
333 which included E gene RT-PCR from a consistent RT-PCR testing platform (APL LDT), we  
334 were able to assess the specificity of the ID NOW and examine the relationship of E gene Ct  
335 values between true positive and false negative ID NOW results.

336

337 Our study had several limitations. Due to the heterogeneity of our populations tested, it is  
338 difficult to exclude confounders that may have contributed to ID NOW performance. However,  
339 no differences were observed in sensitivity based on common patient, collecting and testing  
340 characteristics, including age, gender, swab used, and variants of concern detected. Specificity  
341 was increased for RT-PCR samples collected using oropharyngeal swabs, but this difference was  
342 slight and limited to symptomatic populations. Exclusion of some ID NOW positive results from  
343 our study because of no parallel RT-PCR testing did have an impact on ID NOW performance,  
344 as evidenced by improved sensitivity (93.5% vs 92.5%), among symptomatic community

345 patients presenting to assessment centres, when including these positive samples. Reasons  
346 behind missing parallel RT-PCR are multifactorial and include sample lost or discarded prior to  
347 testing, testing sites going against guidelines and not obtaining a second swab for RT-PCR  
348 confirmation, and patient demographic mismatches resulting in test cancellation or inability to  
349 match ID NOW and RT-PCR tests together in our electronic database. These excluded samples,  
350 however, would have little impact on ID NOW sensitivity and specificity outside of symptomatic  
351 individuals presenting to assessment centres. For instance, no significant changes in sensitivity  
352 among asymptomatic community patients that presented to assessment centres were observed  
353 when the 1822 excluded positive results were subsequently analyzed.

354  
355 In conclusion, the performance of the ID NOW differs across populations tested for SARS-CoV-  
356 2. ID NOW performance can be maximized if testing is limited to symptomatic individuals  
357 presenting to community testing sites (assessment centres). Sensitivity drops by approximately  
358 10% when the testing population is asymptomatic. ID NOW performance is not affected by age,  
359 gender, or variants of concern (alpha, delta). ID NOW testing with combined oropharyngeal +  
360 nasal swab had no effect on performance.

361

362

### 363 **Acknowledgments**

364 This work was funded using internal operating funds of Alberta Precision Laboratories and  
365 Alberta Health Services. Test kits and instruments were paid for by the Public Health Agency of  
366 Canada. We thank staff at AHS assessment centre, mobile teams, and staff at shelters and  
367 addiction recovery sites for collecting and testing samples in the community, and Alberta

368 Precision Laboratory staff for assistance with testing of samples, and in the development and  
369 support of the various testing programs.

370

371

## 372 **Declarations**

373 *Funding:* Internal funding from Alberta Precision Laboratories.

374 *Conflict of Interest:* The manufacturer had no role to play in the study. The authors have no  
375 conflict of interests to disclose pertaining to this study.

376 *Availability of data:* Available upon request.

377

378

## 379 **REFERENCES**

- 380 1. United States Food and Drug Administration. ID NOW COVID-19 – instructions for use.  
381 2020. [Accessed Feb 10, 2022]. Available from:  
382 <https://www.fda.gov/media/136525/download>
- 383 2. Fung B, Gopez A, Servellita V, Arevalo S, Ho C, Deucher A, Thornborrow E, Chiu C,  
384 Miller S. Direct comparison of SARS-CoV-2 analytical limits of detection across seven  
385 molecular assays. *J Clin Microbiol*. 2020 Aug 24;58(9):e01535-20.
- 386 3. Lephart PR, Bachman MA, LeBar W, et al. Comparative study of four SARS-CoV-2  
387 Nucleic Acid Amplification Test (NAAT) platforms demonstrates that ID NOW  
388 performance is impaired substantially by patient and specimen type. *Diagn Microbiol*  
389 *Infect Dis*. 2020;99(1):115200.
- 390 4. Dinnes J, Deeks JJ, Berhane S, et al. Rapid, point-of-care antigen and molecular-based  
391 tests for diagnosis of SARS-CoV-2 infection. *Cochrane Database Syst Rev*.  
392 2021;3:CD013705.
- 393 5. Stokes W, Kanji JN, Hu J, Zelyas N, Berenger BM. Wide variation in threshold cycle  
394 values clouds the interpretation of SARS-CoV-2 infectiousness. *Clin Chem*.  
395 2021;68(1):253-255.
- 396 6. Vlek ALM, Wesselius TS, Achterberg R, Thijsen SFT. Combined throat/nasal swab  
397 sampling for SARS-CoV-2 is equivalent to nasopharyngeal sampling. *Eur J Clin*  
398 *Microbiol Infect Dis*. 2021;40(1):193-195.
- 399 7. Desmet T, Paepe P, Boelens J, et al. Combined oropharyngeal/nasal swab is equivalent to  
400 nasopharyngeal sampling for SARS-CoV-2 diagnostic PCR. *BMC Microbiol*.  
401 2021;22;21(1):31. PMID: 33482729.
- 402 8. Lee RA, Herigon JC, Benedetti A, Pollock NR, Denkinger CM. Performance of saliva,  
403 oropharyngeal swabs, and nasal swabs for SARS-CoV-2 molecular detection: a  
404 systematic review and meta-analysis. *J Clin Microbiol*. 2021;59(5):e02881-20.



- 405 9. Pabbaraju, et al. Development and validation of reverse transcriptase-PCR assays for the  
 406 testing of SARS-CoV-2. *JAMMI*. 2020. Doi:10.3138/jammi-2020-0026: e20200026  
 407 10. Stokes W, Berenger BM, Singh T, et al. Acceptable performance of the Abbott ID NOW  
 408 among symptomatic individuals with confirmed COVID-19. *J Med Microbiol*.  
 409 2021;70(7):001372. PMID: 34309503.

410  
 411  
 412  
 413  
 414

Table 1: Characteristics between individuals tested with ID NOW SARS-CoV-2 using oropharyngeal swabs or combined oropharyngeal and nasal (O+N) swabs.

Site	Symptoms	Mean age (median, range)	Male gender (%)	NP swab used for parallel RT-PCR testing* (%)
<b>OROPHARYNGEAL SWAB FOR ID NOW TESTING</b>				
Assessment centre	Symptomatic (n=70,879)	34.7 (34.4, 0.04-101)	40.5%	49.9%
	Asymptomatic** (n=10,818)	34.5 (32.4, 0.1-102)	46.8%	40.7%
Hospital	Symptomatic (n=16,924)	50.7 (53.6,0.0007-107.9)	48.0%	90.2%
emergency shelters and addiction treatment facilities	Symptomatic (n=1,927)	42.2 (39.2, 2.7-101.2)	60.8%	14.2%
Mobile unit	Symptomatic (n=4,224)	31.8 (31.1, 0.001-103.9)	38.9%	15.5%
	Asymptomatic (n=19,578)	51.4 (47.8,0.5-107.2)	43.5%	56.0%
<b>COMBINED OROPHARYNGEAL AND NASAL SWAB FOR ID NOW TESTING</b>				
Assessment centre	Symptomatic (n=3890)	35.6 (35.9, 0.7-98.3)	40.8%	68.7%
	Asymptomatic** (n=681)	31.2 (29.1,3.4-83.1)	48.6%	76.8%
emergency shelters and addiction treatment facilities	Symptomatic (n=191)	40.6 (39.4,19.1-68.2)	62.8%	1.1%

415 NP: nasopharyngeal  
 416 \*Either NP or oropharyngeal swab was used for parallel RT-PCR testing. In hospitalized patients, a minority of samples were other specimen  
 417 types such as endotracheal tube aspirates.  
 418 \*\*Asymptomatic close contacts only

419  
 420  
 421

422  
423  
424  
425  
426  
427  
428  
429  
430  
431


Table 2: Performance of ID NOW, compared to RT-PCR, using oropharyngeal swabs or combined oropharyngeal and nasal (O+N) swabs.

<b>Oropharyngeal Swab</b>				<b>O+N Swab</b>			
<b>Assessment Centre: Symptomatic</b>				<b>Assessment Centre: Symptomatic</b>			
		RT-PCR				RT-PCR	
		Positive	Negative			Positive	Negative
ID	Positive	9833	315	ID	Positive	335	18
NOW	Negative	800	59,931	NOW	Negative	28	3,509
<b>Assessment Centre: Asymptomatic</b>				<b>Assessment Centre: Asymptomatic</b>			
		RT-PCR				RT-PCR	
		Positive	Negative			Positive	Negative
ID	Positive	768	73	ID	Positive	35	5
NOW	Negative	140	9,837	NOW	Negative	10	631
<b>Emergency Shelters and Addiction Treatment Facilities</b>				<b>Emergency Shelters and Addiction Treatment Facilities</b>			
		RT-PCR				RT-PCR	
		Positive	Negative			Positive	Negative
ID	Positive	62	8	ID	Positive	3	0
NOW	Negative	19	1838	NOW	Negative	1	187
<b>Hospital</b>							
		RT-PCR					
		Positive	Negative				
ID	Positive	2,624	97				
NOW	Negative	308	13,895				
<b>Mobile: Symptomatic</b>							
		RT-PCR					
		Positive	Negative				
ID	Positive	529	22				
NOW	Negative	72	3,601				
<b>Mobile: Asymptomatic</b>							
		RT-PCR					
		Positive	Negative				
ID	Positive	365	78				
NOW	Negative	129	19,006				

432  
433  
434  
435

436  
437  
438  
439  
440  
441  
442  
443

Figure 1: Sensitivity and specificity of ID NOW (oropharyngeal swab) compared to RT-PCR (oropharyngeal swab or nasopharyngeal swab). Error bars represent 95% confidence intervals. AC = assessment centre.



444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463

464  
465  
466  
467  
468

Table 3: Cycle threshold of ID NOW true positives (ID NOW +, RT-PCR +) and false negatives (ID NOW -, RT-PCR +) between sites and populations tested.

Site	Symptomatic vs Asymptomatic	Variant (%)	Mean E gene Ct of true positives (median, range)	Mean E gene Ct of false negatives (median, range)
<b>OROPHARYNGEAL SWAB</b>				
Assessment centre	Symptomatic	Wild-type (13.3%) Delta (41.1%) Alpha (33.6%) Unresolved (8.0%) Other** (2.0%)	23.4 (22.6, 13.8-41.0)	29.7 (31.6, 14.7-41.0)
	Asymptomatic*	Wild-type (18.9%) Delta (17.6%) Alpha (43.5%) Unresolved (19.0%) Other** (1.1%)	26.2 (26.2, 13.9-38.4)	31.8 (33.2, 18.5-40.7)
Emergency shelters and addiction treatment facilities	Symptomatic	Wild-type (35.6%) Delta (35.6%) Alpha (10.2%) Unresolved (16.9%) Other** (0.5%)	25.9 (26.2, 15.0-35.7)	36.3 (36.3, 34.5-38.1)
Hospital	Symptomatic	Wild-type (3.7%) Delta (72.2%) Alpha (12.8%) Unresolved (10.1%) Other** (1.1%)	22.8 (22.0,13.7-41.0)	30.2 (31.6, 15.5-39.9)
Mobile	Symptomatic	Wild-type (10.8%) Delta (49.4%) Alpha (25.9%) Unresolved (12.7%) Other** (1.1%)	25.3 (24.9, 14.7-37.7)	33.0 (34.3, 18.8-38.1) <sup>#</sup>
	Asymptomatic	Wild-type (17.6%) Delta (20.3%) Alpha (26.5%) Unresolved (32.7%) Other** (2.9%)	26.7 (27.0, 14.9-40)	33.9 (34.9,18.2-41.0) <sup>#</sup>
<b>COMBINED OROPHARYNGEAL AND NASAL (O+N) SWAB</b>				
Assessment centre	Symptomatic	Wild-type (59.3%) Alpha (28.4%) Unresolved (12.1%)	22.6 (21.6,14.0-38.6)	28.4 (32.4,15.3-38.1) <sup>#</sup>
	Asymptomatic*	Wild-type (32.7%) Alpha (32.7%) Unresolved (34.7%)	25.1 (25.2,15.3-38.1)	30.4 (28.3,26.2-36.7) <sup>#</sup>

469  
470  
471  
472  
473  
474  
475  
476  
477  
478


\*Asymptomatic close contacts only

\*\*Beta, Gamma, non-variant of concern, Unknown)

<sup>#</sup>P<0.01 for all comparisons of mean E gene Ct of true positives vs false negatives and symptomatic vs asymptomatic within each group, with the exception of false negatives between symptomatic vs asymptomatic in mobile testing and in assessment centres using O+N swabs (p>0.05).

479  
480  
481  
482  
483

Figure 2: Sensitivity and specificity of ID NOW, compared to RT-PCR, for ID NOW specimens collected using either oropharyngeal swab or combined oropharyngeal and nasal (O+N) swab at COVID-19 assessment centres. Error bars represent 95% confidence intervals.



484